849758-52-7
Chemical Structure
Bevasiranib sodium
- CAS No.: 849758-52-7
- Formula:N/A
- Molecular Weight:13345.2 (free acid)
SMILES: [Bevasiranib (sodium)]
Biological Activity: Bevasiranib sodium is a siRNA that targets and silences VEGF-A. Bevasiranib sodium activates the RNA-induced silencing complex to degrade VEGF-A mRNA, mediates TLR3-related inhibition of choroidal neovascularization, and triggers RNA interference-mediated gene silencing through endogenous eukaryotic RNAi mechanisms. After intravitreal injection, Bevasiranib sodium distributes to various ocular tissues and resists degradation by intraocular nucleases, reducing choroidal neovascularization area and alleviating vascular leakage. Bevasiranib sodium can be used in research related to macular degeneration[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bevasiranib sodium | 97.99% | Bevasiranib sodium is a siRNA that targets and silences VEGF-A. Bevasiranib sodium activates the RNA-induced silencing complex to degrade VEGF-A mRNA, mediates TLR3-related inhibition of choroidal neovascularization, and triggers RNA interference-mediated gene silencing through endogenous eukaryotic RNAi mechanisms. After intravitreal injection, Bevasiranib sodium distributes to various ocular tissues and resists degradation by intraocular nucleases, reducing choroidal neovascularization area and alleviating vascular leakage. Bevasiranib sodium can be used in research related to macular degeneration. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Garba AO, et al. Bevasiranib for the treatment of wet, age-related macular degeneration. Ophthalmology and eye diseases. 2010;2:75-83. [Content Brief]
- [2]. Dejneka NS, et al. Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Molecular vision. 2008 May 28;14:997-1005. [Content Brief]
